Plasma microRNAs (miRNAs) have been proposed as potential biomarkers in Alzheimer's
disease (AD). Here, we explored their use as early sensors of the preclinical phase of the …

The development of Alzheimer's disease (AD) biomarkers remains an unmet challenge, and
new approaches that can improve current AD biomarker strategies are needed. Recent …

The identification of reliable biomarkers for Alzheimer's disease (AD) remains challenging.
Recently, abnormal levels of microRNAs (miRNAs) miR-27a, miR-29a, miR-29b, and miR …

Several micro (mi) RNA are deregulated in brain, cerebrospinal fluid (CSF), and
serum/plasma from patients with Alzheimer's disease (AD). The aim of the study was to …

MicroRNAs (miRNAs) are attractive molecules to utilize as one of the blood-based
biomarkers for neurodegenerative disorders such as Alzheimer's disease (AD) because …

Background Several evidences suggest that failure of synaptic function occurs at preclinical
stages of Alzheimer's disease (AD) preceding neuronal loss and the classical AD …

There is an urgent need to identify non-invasive biomarkers for the detection of sporadic
Alzheimer's disease (AD). We previously studied microRNAs (miRNAs) in AD autopsy brain …

Background MicroRNAs (miRNAs) are endogenous small RNAs of 21–25 nucleotides that
post-transcriptionally regulate gene expressions. Recently, circulating miRNAs have been …

The microRNAs (miRNAs) are potential biomarkers for complex pathologies due to their
involvement in the regulation of several pathways. Alzheimer Disease (AD) requires new …

The purpose of our study was to identify microRNAs (miRNAs) as early detectable
peripheral biomarkers in Alzheimer's disease (AD). To achieve our objective, we assessed …